BCA101

Other Medications

Experimental

Not available 1 Clinical Trials

Description

BCA101 is an experimental medication currently being studied in clinical trials for certain advanced solid tumors. It is being investigated as a potential treatment option, sometimes in combination with other drugs like pembrolizumab. In colorectal cancer trials, BCA101 is being studied specifically in patients whose tumors have EGFR mutations and/or express PD-L1. The goal of these early-phase trials (Phase 1) is primarily to determine the safety and tolerability of BCA101, both when given alone and in combination with pembrolizumab, and to find the best dose for further studies. It is not yet approved for treating colorectal cancer or any other cancer.

Mechanism of Action

BCA101 is being studied as a potential therapy for cancers driven by EGFR mutations. The specific way BCA101 works (its molecular target or mechanism of action) is still being investigated in clinical trials. It is designed to target pathways involved in tumor growth and survival, potentially interfering with the signals that EGFR mutations cause in cancer cells. It is being tested alone and in combination with pembrolizumab, an immunotherapy drug, to see if this combination is effective and safe.

Side Effects

As BCA101 is an investigational drug in early-phase clinical trials The full range of potential side effects is still being evaluated. The primary focus of Phase 1 trials is to assess safety and determine the maximum tolerated dose. Common side effects observed in early trials of cancer drugs can include fatigue Nausea Diarrhea Skin reactions And changes in blood counts. Specific side effects related to BCA101 will become clearer as more patients are treated in ongoing and future trials. Patients participating in these trials are closely monitored for any adverse events.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT04429542 Phase 1

Recruiting

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

United States, Australia, Canada

Quick Info

Category	Other Medications
EMA Status	Experimental
Spain Access	Not available
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.